Unbiased Analysis of Today's Healthcare Issues
That is the question a new paper by Chambers et al. (2025) aims to answer. The authors use data from the Specialty Drug Evidence and Coverage (SPEC) Database, which contains coverage policies related to specialty pharmacy for a large number of US health plans, to examine how n=25 cell and gene therapies are being covered…
That is the title of my recent publication with co-authors Andrea Chung, Sachin Vadgama, Kristen Hurley, Miguel-Angel Perales, Leonard Clarkson Alsfeld, Sanjana Muthukrishnan and Anik R Patel, Gunjan L Shah, Richard T Maziarz. The abstract is below. CAR T-cell therapy has shown curative potential for patients with diffuse large B-cell lymphoma (DLBCL) and other malignancies,…
A paper by Drummond et al. (2023) examines how health technology assessment bodies deal with the challenge of value assessment for cell and gene therapies (also known as Advanced Therapy Medicinal Products (ATMPs) in Europe). To do this the authors: …undertook i) a targeted review of the literature on the clinical and economic evidence needs…
Cell and gene therapies have the potential to produce dramatic improvements in quality of life and survival for severe and often rare diseases. Currently, however, the cost of these treatments is high and access is sometimes limited. To identify some of these challenges in Europe EURODIS conducted an evaluation of country-specific challenges with respect to…